The origins of Daiichi Sankyo in Switzerland date back to 1998. Since 2022, the company has been under the management of Giuseppe Giulio Grossi and operates as an organization with over 50 employees.
The main focus of Daiichi Sankyo (Schweiz) AG is on the distribution of cardiovascular and oncological drugs.
A promising pipeline of innovative applications is aimed at various fields of application.